In Brief
FDA Grants Acute Pain Investigational New Drug Status for Non-Opioid Nefopam
Analgesic study of oral nefopam shows promise for extended pain relief and safety in phase 2 trials.
JULY 20, 2026
Diversion Software Success Hinges On Trust, Workflow, and Follow-Through
Drug diversion software implementation succeeds with trust, workflow alignment, and communication, not just ...
JULY 16, 2026
More Research Needed on Fast-Acting Drugs for Breathlessness
Dyspnea treatments show unclear evidence for quick relief and safety in acute cases.
JUNE 9, 2026
FDA Approves Novel Nonopioid Treatment for Moderate-to-Severe Acute Pain
The FDA has approved suzetrigine (Journavx, Vertex Pharmaceuticals) 50 mg oral tablets as a first-in-class ...
JANUARY 31, 2025
NIH Ends Study of Tecovirimat as Mpox Pain Treatment
The NIH has halted a study testing tecovirimat as a treatment for patients with mpox after the drug showed no ...
JANUARY 27, 2025
Better Algorithms Needed for Predicting Opioid Use Disorder
There is a need for more robust data and improved machine learning techniques to accurately assess the genetic risk ...
JANUARY 17, 2025
FDA Issues New Guidance, Clarifies Confusion on Buprenorphine Labeling
The FDA has issued new guidance for labeling buprenorphine-containing transmucosal products that seeks to clarify ...
JANUARY 16, 2025
FDA Grants 510(k) Clearance for Updated Cryoneurolysis System for LBP
The ioveraº system is an FDA-cleared, drug-free treatment that relieves pain via cryoneurolysis.
JANUARY 14, 2025
Patients, Providers Provide Perspectives on Opioid Diversion in Canada’s Safer Supply Programs
Safer pharmaceutical-grade alternatives to toxic and unregulated supplies of opioids could help address opioid ...
JANUARY 9, 2025
FDA Approves Atogepant to Prevent Chronic Migraine in Adults
Atogepant becomes the first oral CRGP receptor antagonist approved to prevent both episodic and chronic ...
APRIL 19, 2023
FDA Grants De Novo Status to Opioid Overdose Prevention and Alert System
Opioid Halo will be available OTC and by prescription
APRIL 12, 2023
FDA Accepts sNDA for Nerve Blocks in Lower Extremity Procedures
The label expansion would include single-dose sciatic nerve block in the popliteal fossa and femoral nerve block in ...
APRIL 11, 2023
